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Background: Hypersecretion of mucin in the airway epithelium is an important feature of allergic airway
diseases. Of the 3 cysteinyl leukotrienes (CysLTs; LTC4 LTD4 and LTE4), only LTE4 is sufﬁciently stable to be
detectable in extracellular ﬂuids. However, LTE4 has received little attention because it binds poorly to
the CysLT1 and CysLT2 receptors; therefore, little is known about the effects of LTE4 on mucous secretion.
Recently, studies have focused on the P2Y12 receptor as a potential receptor for LTE4, because this re-
ceptor is required for LTE4-mediated pulmonary inﬂammation. In our previous study, we conﬁrmed the
expression of P2Y12 receptor in human airway epithelial cells. To clarify the roles of LTE4 in airway
epithelial cells, we investigated mucus secretion by LTE4 in vitro.
Methods: Conﬂuent NCI-H292 cells were stimulated with LTE4 (0.01e1 mM) for 24 h. The release and
production of MUC5AC protein, a gel-forming mucin, were evaluated with an enzyme-linked immu-
nosorbent assay.
Results: Western blot analysis revealed that NCI-H292 cells expressed P2Y12 receptor protein. LTE4
signiﬁcantly induced the release of MUC5AC mucin in a dose-dependent manner. Th2 cytokines such as
IL-4 (10 ng/mL) and IL-13 (10 ng/mL) accelerated the LTE4-induced release of MUC5AC protein. MRS2935,
a P2Y12 receptor antagonist, partially inhibited the LTE4-induced release of MUC5AC protein in the
airway. In contrast, MK571, a CysLT1 receptor antagonist, did not affect the release of MUC5AC protein
elicited by LTE4.
Conclusions: These results suggest that LTE4 may play some important roles in allergic mucus secretion
partially via activation of P2Y12 receptor.
Copyright © 2014, Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.Introduction
The allergic response is a complex process involving the inter-
action of manymediators. Cysteinyl leukotrienes (CysLTs) are one of
the most important mediators in the pathogenesis of airway
allergic diseases such as allergic rhinitis and asthma.1 LTE4 is the
most stable CysLT and can remain active at the site of release for a
prolonged period after its synthesis.2 Although LTE4 is a weak
agonist of classical receptors for CysLTs (CysLT1 and CysLT2),3,4
administration of exogenous LTE4 into the human airway causes
airway obstruction and mucosal eosinophilia in patients with
asthma.5e7 P2Y12 is the major platelet receptor that mediates ADP-




rgology. Production and hosting by Elsbe a surrogate ligand for P2Y12 receptor,9 and purinergic P2Y12
receptor was shown to be required for LTE4-mediated pulmonary
inﬂammation.10,11 Recently, we detected expression of P2Y12 re-
ceptor in epithelial cells and submucosal glands in human allergic
and non-allergic nasal mucosa by western blotting and immuno-
histochemical analysis,12 indicating its potential role in the allergic
response.
Mucus hypersecretion from the airway epithelium is a feature of
asthma and allergic rhinosinusitis, and airwaymucin is synthesized
by epithelial goblet cells and submucosal glands, which may ex-
press P2Y12 receptor as shown in our previous study.12 Moreover,
little is known about the effects of LTE4 onmucous secretion such as
that of MUC5AC mucin, which is a major gel-forming mucin in the
airway. In a preliminary study, MUC5AC protein in the mediumwas
undetectable under conventional cell culture conditions. Previous
reports showed that retinoic acid13 or epidermal growth factor
(EGF)14 could alter MUC5AC protein in a human airway epithelial
cell line, NCI-H292; therefore, we here evaluated the level of
MUC5AC mucin in retinoic acid and EGF-pretreated cells. Weevier B.V. All rights reserved.
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release of MUC5AC protein in NCI-H292 cells.
Methods
Culture of NCI-H292 cells
Cells of a human lungmucoepidermoid carcinoma cell line (NCI-
H292) were purchased from the American Type Culture Collection.
Cell suspensions were plated onto collagen type I-coated 6-well
culture plates (Asahi Glass Co., Ltd., Funabashi, Japan) for a
MUC5AC enzyme-linked immunosorbent assay (ELISA) or on
collagen type 1 coated 4-well culture slides (Becton Dickinson
Biosciences Discovery Labware, Bedford, MA, USA) for immuno-
chemistry. The cells were cultured in RPMI-1640 medium (Sigma,
St Louis, MO, USA) supplemented with 10% fetal bovine serum, L-
glutamine, and antibiotics (50 U/mL penicillin and 50 mg/mL
streptomycin) and cultured in a 5% carbon dioxide humidiﬁed at-
mosphere at 37 C. The culture medium was changed at day 1 and
every 2 days thereafter. To overexpress mucin, conﬂuent cells were
pretreated with 20 ng/mL EGF (Sigma) and 100 nM retinoic acid
(Sigma) for 48 h.
Primary cultured human tracheal and nasal epithelial cells
Primary cultured human tracheal epithelial cells (HTECs) and
primary cultured human nasal epithelial cells (HNECs) were used
for western blot analyses of P2Y12 receptor expression. HTECs were
purchased from Lonza Japan Ltd (Tokyo, Japan), and the cells were
cultured according to the manufacturer instructions. To obtain
nasal epithelial cells, we used surgical specimens. Human inferior
turbinates were obtained after turbinectomy from 3 patients with
nasal obstruction that were refractory tomedical therapy. Informed
consent was obtained from the patients, and this study was
approved by the ethics committee of Sapporo Medical University
(approval number: 24-14). HNECs were isolated from human nasal
mucosa specimens according to a previously described protocol.15
Cell suspensions were plated onto collagen type-I-coated 6-well
culture plates in Ham's HD medium and cultured in a 5% carbon
dioxide humidiﬁed atmosphere at 37 C. The culture medium was
changed at day 1 and every 2 days thereafter. Monolayer cell
conﬂuence was achieved after 6e8 days of culture．Morphological
observations using a phase contrast microscope showed that these
cultured cells consisted primarily of epithelial cells. More than 95%
of these cells showed positive reactions for anti-human cytokeratin
antibody (Dako, Glostrup, Denmark). HTECs and HNECs grown to
80% conﬂuence were used for western blot analysis.
Immunohistochemistry for MUC5AC mucin
For immunohistochemistry of MUC5AC mucin, a mouse anti-
human MUC5AC monoclonal antibody against the MUC5AC pep-
tide corresponding to the core of gastric mucin (Acris Antibodies,
Inc., San Diego, CA, USA) was used at 1:150 dilutions. NCI-H292
cells on the culture slides were initially washed with phosphate-
buffered saline (PBS), and the cells were ﬁxed by 100% methanol
and 100% acetone each for 5 min at 20 C. After air-drying for
5 min, the sections were incubated in blocking solution (10%
normal goat serum in PBS) for 30 min before incubation in primary
antibody. Then, the sections were incubated with anti-MUC5AC
monoclonal antibody for 2 h at room temperature. Sections were
washed in PBS andwere incubated for 30minwith Alexa Fluor 594-
labeled goat anti-mouse IgG (diluted 1:50; Molecular Probes,
Eugene, OR, USA). Sections were mounted with Vectashield®
mounting medium with 40,6 diamidino-2-phenylindole (VectorLaboratories Inc., Burlingame, CA, USA) and examined under an
Olympus BX51 microscope, attached to a DP70 CCD camera
(Olympus Optical Co., Ltd., Tokyo, Japan). All imageswere processed
with DP Controller and DPManager Software (Olympus Optical Co.,
Ltd.) for image analysis. Negative controls were obtained by
replacing primary antibodies with mouse IgG1 (Dako).
Western blot analysis
For western blot of P2Y12 receptor, rabbit anti-human P2Y12 re-
ceptor polyclonal antibody (product number P4871, Sigma) was
used at 4 mg/ml concentration. For western blot analysis, NCI-H292
cells, HTECs, or HNECs were homogenized in T-PER Tissue Protein
Extraction Reagent (Thermo Fisher Scientiﬁc Inc., Waltham, MA,
USA), supplemented with a proteinase inhibitor cocktail (Sigma).
The protein extracts were puriﬁed by using PAGEprep Advance Kit
(Thermo Fisher Scientiﬁc Inc.). Protein concentration in the ho-
mogenates was determined using a BCA Protein Assay Kit (Thermo
Fisher Scientiﬁc Inc.). Protein extracts (20 mg protein each) were
separated on a 4e12% sodium dodecyl sulfate-polyacrylamide gel
and blotted onto a polyvinylidene diﬂuoride membrane (Invitrogen
Corporation, Carlsbad, CA, USA). Membranes were then blocked and
probed with rabbit anti-human P2Y12 receptor polyclonal antibody
(Sigma). The bands were visualized using a WesternBreeeze chro-
mogenic western blot immunodetection kit (Invitrogen).
MUC5AC mucin analysis using ELISA
MUC5AC protein levels in the cellular secretions and lysates
were evaluated by ELISA. Conﬂuent NCI-H292 cells pretreated with
EGF (20 ng/ml) and retinoic acid (100 nM) for 48 h were stimulated
with 0.01e1 mM LTE4 (Cayman Chemical Co., Ann Arbor, MI, USA)
for 24 h. To determine the effects of Th2 cytokines on the LTE4-
induced release of MUC5AC protein, the cells were exposed to
10 ng/mL IL-4 (Sigma) and 10 ng/mL IL-13 (Sigma). To ascertain
whether LTE4 could mediate signal transduction through the P2Y12
receptor or CysLT1 receptor, the inhibitory effects of a receptor-
speciﬁc antagonist for P2Y12 receptor or a CysLT1 receptor antago-
nist on LTE4-induced mucous secretion were also examined. The
cells were stimulated with LTE4 alone or LTE4 in combinationwith a
P2Y12 receptor antagonist, MRS2395 (1e10 mM; Sigma) or a CysLT1
receptor antagonist, MK571 (10 mM; Cayman Chemical Co.) for 24 h.
The culture medium was collected at 24 h after the stimulations
with LTE4 or control vehicle. Cells were washed with PBS, and the
cells were lysed in T-PER Tissue Protein Extraction Reagent. Protein
concentration in the cell lysates was determined using a BCA Pro-
tein Assay Kit. The levels of MUC5AC protein in the culture medium
and cell lysates were evaluated by using ELISA kits (USCN Life Sci-
ence Inc., Wuhan, China). The detection range of the kits is
0.312e20 ng/mL.
Statistical analysis
MUC5AC levels were determined in triplicate from 5 separate
experiments and are presented as mean ± SD. Where appropriate,
statistical differences were assessed by a non-parametric Man-
neWhitney U test. P-values 0.05 were considered statistically
signiﬁcant.
Results
Immunohistochemical analyses for MUC5AC mucin
We evaluated the level of MUC5AC mucin in retinoic acid and
EGF-pretreated cells by immunohistochemistry. As shown in
H. Shirasaki et al. / Allergology International 64 (2015) 169e174 171Fig. 1A, the pretreatment with EGF and retinoic acid increased
MUC5AC protein expression in NCI-H292 cells relative to untreated
control cells (Fig. 1B). Speciﬁcity of the staining was conﬁrmed by
absence of labeling with normal mouse immunoglobulin (Fig. 1C).
Western blotting for P2Y12 receptor
In order to conﬁrm expression of P2Y12 receptor in human
airway epithelial cells, western blot analysis was performed. As
shown in Fig. 2, expression of a single band for P2Y12 receptor
protein in human airway epithelial cells was clearly demonstrated.Fig. 1. Immunoﬂuorescence staining for MUC5AC mucin in NCI-H292 cells. (A) Pre-
treatment with EGF and retinoic acid for 48 h increased MUC5AC protein expression.
(B) Appearance of cells under conventional cell culture conditions without EGF and
retinoic acid. (C) Negative control staining with normal mouse immunoglobulin. Scale
bar ¼ 100 mm.
Fig. 2. Representative western blots for the P2Y12 receptor protein in human airway
epithelial cells (lane 1: primary cultured human nasal epithelial cells, lane 2: primary
cultured human tracheal epithelial cells, lane 3; NCI-H292 cells). The antibody
recognized a single protein of 55 kDa referred to as P2Y12 receptor.Therefore, these primary cultured human airway epithelial cells
and NCI-H292 cells expressed P2Y12 receptor protein.
LTE4 induced the release of MUC5AC mucin
MUC5AC protein levels in the cellular secretions and lysates
were evaluated by ELISA. As shown in Fig. 3A, LTE4 signiﬁcantly
induced the release of MUC5AC mucin in a dose-dependent
manner. After the addition of 1 mM of LTE4, there was a 3-fold in-
crease in MUC5AC concentration (control, 1.3 ± 0.3 ng/mL; LTE4
1 mM, 3.8 ± 0.7 ng/mL). By contrast, the cellular content of MUC5AC
mucin tended to decrease in a dose -dependent manner (Fig. 3B).
To determine the effects of Th2 cytokines on the LTE4-induced
release of MUC5AC protein, the cells were exposed to Th2 cyto-
kines. As shown in Fig. 4A, Th2 cytokines such as IL-4 and IL-13
accelerated the LTE4-induced release of MUC5AC protein (LTE4
1 mM alone, 3.4 ± 0.5 ng/mL; L-4 10 ng/mL and IL-13 10 ng/mL,
3.4 ± 0.6 ng/mL; LTE4 1 mM plus IL-4 10 ng/mL and IL-13 10 ng/mL,
4.3 ± 0.5 ng/mL). As shown in Fig. 4B, Th2 cytokines tended to in-
crease the cytoplasmic MUC5AC concentration even in LTE4-stim-
ulated cells (LTE4 1 mM alone, 17.1 ± 3.5 ng/mL; L-4 10 ng/mL and IL-
13 10 ng/mL, 29.1 ± 6.3 ng/mL; LTE41 mMplus IL-4 10 ng/mL and IL-
13 10 ng/mL, 21.9 ± 4.8 ng/mL).
To clarify whether LTE4 could mediate signal transduction
through the P2Y12 receptor or CysLT1 receptor, the inhibitory effects
of a receptor-speciﬁc antagonist for P2Y12 receptor or a CysLT1 re-
ceptor antagonist on LTE4-induced mucous secretion were exam-
ined. As shown in Fig. 5, MRS2395, a P2Y12 receptor antagonist,
could partially inhibit the LTE4-induced release of MUC5AC protein
(control, 0.8 ± 0.2 ng/mL; LTE4 1 mM alone, 3.5 ± 0.6 ng/mL; LTE4
1 mM plus MRS2935 10 mM, 2.0 ± 0.3 ng/mL). By contrast, MK571, a
CysLT1 receptor antagonist, did not affect the release of MUC5AC
protein elicited by LTE4. (LTE4 1 mM alone, 3.5 ± 0.6 ng/mL; LTE4
1 mM plus MK571 10 mM, 3.7 ± 0.5 ng/mL).
Discussion
In the present study, we used retinoic acid and EGF-pretreated
NCI-H292 cells to study mucin secretion. NCI-H292 is an epithe-
lial cell line that has been frequently used as an in vitro model
system to study gene regulation and signal transduction.16 We also
conducted in vitro experiments using BEAS-2B cells, primary
cultured HTECs, and primary cultured HNECs to detect MUC5
mucin secretion at protein level. Unfortunately, we could not detect
any mucins secreted from these epithelial cells by ELISA and
western blot analysis. Therefore, retinoic acid and EGF-pretreated
NCI-H292 cells may be useful for studies of MUC5AC secretions in
airway epithelial cells.
Fig. 3. LTE4 induced the release of MUC5AC mucin from NCI-H292 cells. (A) LTE4 signiﬁcantly induced the release of MUC5AC mucin in a dose-dependent manner. (B) The cellular
content of MUC5AC mucin tended to decrease in a dose-dependent manner by LTE4. The data are the means ± SD for 5 independent experiments. *p < 0.05 by Mann-Whiteney U
test.
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human airway epithelial cells by LTE4. To the best of our knowledge,
this represents the ﬁrst report demonstrating the effect of LTE4 on
mucous secretion from airway epithelial cells. One previous study
evaluated the role CysLTs in mucin secretion of human airway
epithelial cells, which demonstrated that pranlukast, a CysLT1 re-
ceptor antagonist, decreased LTD4-induced MUC2/5AC gene
expression and mucin secretion in cultured NCI-H292 cells.17 Ishi-
naga et al. reported that pranlukast inhibited MUC2 gene tran-
scription through pathways distinct from CysLT1 receptor
antagonism in NCI-H292 cells, because reverse transcription-
polymerase chain reaction (RT-PCR) showed that NCI-H292 cells
did not express CysLT1 receptor.18 In addition, we conﬁrmed that
NCI-H292 cells do not natively express any known classical CysLTFig. 4. Th2 cytokines such as IL-4 and IL-13 accelerated the LTE4-induced release of MUC5
cytokines. (B) Cytoplasmic MUC5AC concentration. The data are the means ± SD for 5 indereceptors as determined through western blotting and RT-PCR
analyses (data not shown). Therefore, it seems possible that LTD4-
induced mucous secretion from NCI-H292 cells occurred via acti-
vation of LTE4 receptor that was simulated by stable LTE4 converted
from unstable LTD4.
In this study, the release of MUC5AC mucin from NCI-H292 cells
was observed following stimulation with LTE4 at concentration
greater than 0.1 mM (44 ng/mL). Because LTE4 is sufﬁciently stable
to be prominent in biologic ﬂuids, urinary LTE4 is an appropriately
sensitive biomarker for the aspirin-induced asthma.19 Although
many studies concerning the levels of urinary LTE4 have been re-
ported,19 there are few reports about the concentration of LTE4 in
the airway. We have previously reported that the median concen-
tration of CysLTs (LTC4/LTD4/LTE4) in nasal lavage ﬂuid after nasalAC protein. (A) Release of MUC5AC mucin into the culture medium by CysLTs and Th2
pendent experiments. *p < 0.05 by Mann-Whiteney U test.
Fig. 5. The effects of a P2Y12 receptor antagonist on LTE4-induced MUC5AC secretion.
MRS2395, a P2Y12 receptor antagonist, partially inhibited the LTE4-induced release of
MUC5AC protein. In contrast, MK571, a CysLT1 receptor antagonist, did not affect the
release of MUC5AC protein elicited by LTE4. The data are the means ± SD for 5 inde-
pendent experiments. *p < 0.05 by Mann-Whiteney U test.
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that the median concentrations of LTE4 in nasal lavage ﬂuid in
healthy volunteers was 60 pg/mL following exposure to swine
house dust.21 Because these nasal lavage ﬂuid samples were diluted
with saline, it might be possible that the density of local LTE4 was
close to the density required to cause MUC5AC secretion.
The studies of Parruchuri et al. and Maekawa et al. have
demonstrated that LTE4 signaling can occur independently of the
classical CysLT receptors, CysLT1 and CysLT2, indicating that LTE4
preferentially signals via another as-yet-unidentiﬁed CysLT recep-
tor.10,11 As shown in Fig. 2, we found that P2Y12 receptor is
expressed in primary cultured human airway epithelial cells and
NCI-H292 cells. Our previous immunohistochemical studies,
western blotting and RT-PCR analysis clearly showed the expres-
sion of P2Y12 receptor not only in nasal vascular endothelial cells
but also in nasal epithelial cells at the mRNA and protein levels.12 A
previous study also showed that P2Y12 mRNA was expressed in
human primary cultured HNECs by using RT-PCR analysis.21 The
extracellular purines (adenosine, ADP, and ATP) and pyrimidines
(UDP, UTP) regulate various physiological responses via cell-surface
receptors termed purinoreceptors and exert autocrine or paracrine
effects on ion transport,22 ﬂuid transport,23 ciliary beat fre-
quency,22,24 and mucin secretion.25 Thus the purinoreceptors in
airway epithelial cells may play an important role in mucous
secretion under inﬂammatory conditions.
Because the P2Y12 antagonist was able to only partially control
LTE4-induced MUC5AC secretion, other pathways may be involved
in this process. Recently, GPR99, previously reported as an oxy-
glutarate receptor,26 was identiﬁed as a potential LTE4 receptor.27
LTE4 binds to and activates GPR99 at low nanomolar-range con-
centrations in transfected cells, and resists blockage by MK571, a
CysLT1 receptor antagonist.27 Using immunohistochemical analysis,
we recently conﬁrmed that GPR99 protein was present as a dimer
in human nasal mucosa by western blot analysis, and was localized
in epithelial cells, submucosal glands, and inﬂammatory leukocytes
such as eosinophils and macrophages in the nasal mucosa (data not
shown). Unfortunately, there has not been any report about GRP99-
speciﬁc antagonists, although studies using small interfering RNA
against GPR99 are currently in progress in our laboratory to clarify
the role of GRP99 on the LTE4-induced mucous secretion from
epithelial cells.
In conclusion, this study provides important information about
the role of LTE4 on airway mucous secretion. The present ﬁndingsshould be of considerable interest for understanding the potential
roles of LTE4 in allergic airway diseases characterized by hyper-
mucous secretion such as asthma and eosinophilic rhinosinusitis.
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